Go to 7 Dec 2022 8k (EX-99.1). Slide 61 shows 6.

Quote:

---

Go to 7 Dec 2022 8k (EX-99.1). Slide 61 shows 6.

---

Nice find.

Of the 6, 1 dropped out before a PET scan was done and 1 patient didn't show a tumor on the PET scan at start of trial. The patient without a PET scan at the start showed progression after initially showing a drop. Of the 4 that could be assessed from trial start, none showed tumor progression. All 4 showed a reduction in tumor size with 1 showing stable disease and 3 showed a partial response. Tumor reduction varied from approximately 20% to 70%. What confounds things a bit is the time of the PET scans stopped in some before the treatment ended.and the last PET scan done for each patient varied from around 3 months to 7 months. Treatment was in place from 3 months to 11 months.

All patients were given 525mg of leronlimab. The inclusion criteria was based on failing standard therapy with disease progression. Not optimal, but even with that leronlimab showed good effect.

With a standardized trial instead of the variables that get introduced in a basket trial, an almost certainty of everyone ending up on 700mg and the secret weapon of PD-L1 inhibitors I would expect excellent results.